Nurix Therapeutics

Nurix’s president and CEO, Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the RBC Global Healthcare Conference on Wednesday, May 20, 2026, at 1:30 p.m. ET. Listen to the live or archived discussion here: https://bit.ly/4h3qhJ7

Today we announced the presentation of new preclinical and Phase 1 translational data highlighting the potential of bexobrutideg (NX-5948) in chronic spontaneous urticaria (CSU) at the 2026 Society for Investigative Dermatology Annual Meeting.    The findings demonstrate that targeted degradation of BTK may provide broader and deeper suppression of pathogenic immune signaling than BTK inhibition alone, supporting the future clinical development of bexobrutideg in inflammation and immunology indications.    Learn more here: https://bit.ly/4dmVBBY

We’re pleased to announce that updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) will be reported in an oral presentation at the 31st Congress of the European Hematology Association (EHA), taking place June 11-14, 2026, in Stockholm, Sweden.       Learn more here: https://bit.ly/4eIcauC    #EHA2026

This World Cancer Research Month, we stand with the global scientific community working to transform the future of cancer care. At Nurix, we’re advancing targeted protein degradation therapies with the goal of expanding what’s possible for patients facing difficult-to-treat cancers. #CancerResearchMonth

Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., has been selected to speak in an AACR Advances session on induced proximity pharmacology, including targeted protein degradation, on Wednesday, April 22, 2026, at 10:15 am PT. Be sure to listen to the presentation if you’re attending the meeting. #AACR2026 

Tomorrow, Nurix team members Ryan Rountree, Ph.D., Executive Director of Preclinical Pharmacology, Alexandra Borodovsky, Ph.D., Director of Preclinical Pharmacology and Ya-Wen Lu, Ph.D., Director of Discovery Biology will present posters at #AACR2026 highlighting the breadth of Nurix’s research pipeline. Be sure to check out each poster if you’re attending the meeting. 

Nurix’s Senior Vice President and Head of Medicinal, Computational & Analytical Chemistry, Frederick Cohen, Ph.D., will give an oral presentation highlighting Nurix’s discovery and development of CBL-B inhibitors to treat cancer at #AACR2026 on Tuesday, April 21, 2026, at 3:05 p.m. PT     Be sure to catch the presentation if you’re attending the meeting.  

Nurix’s president and CEO, Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 1:30 p.m. ET. Listen to the live or archived discussion here: https://bit.ly/4h3qhJ7

Today we reported financial results for the first quarter of fiscal year 2026 and provided an update highlighting continued execution across our registrational program for bexobrutideg, advancement of our broader pipeline, and multiple anticipated clinical and scientific catalysts in 2026.    Learn more in the press release here: https://bit.ly/4mkZU51

Cancer Control Month is a reminder that progress in cancer care takes more than awareness; it takes innovation, prevention, and continued commitment to patients. At Nurix, we’re advancing first-in-class targeted protein degradation therapies with the goal of unlocking new approaches to treating cancer and other diseases, while recognizing the importance of early detection, prevention, and access to care. Together, each step forward brings us closer to better outcomes for patients. #CancerControlMonth